Netanya G Sandler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5462390/publications.pdf

Version: 2024-02-01

48 papers

5,283 citations

201674 27 h-index 214800 47 g-index

48 all docs 48 docs citations

48 times ranked 8044 citing authors

#	Article	IF	CITATIONS
1	IFNL4 Genotype Does Not Associate with CD4 T-Cell Recovery in People Living with Human Immunodeficiency Virus. AIDS Research and Human Retroviruses, 2021, 37, 184-188.	1.1	2
2	Potential use of <scp>serumâ€derived</scp> bovine immunoglobulin/protein isolate for the management of <scp>COVID</scp> â€19. Drug Development Research, 2021, 82, 873-879.	2.9	5
3	Immune Activation and Inflammation in People With Human Immunodeficiency Virus: Challenging Targets. Journal of Infectious Diseases, 2020, 221, 1567-1570.	4.0	3
4	Timing of Antiretroviral Therapy Initiation Determines Rectal Natural Killer Cell Populations. AIDS Research and Human Retroviruses, 2020, 36, 314-323.	1.1	5
5	Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation. Digestive Diseases and Sciences, 2020, 65, 741-756.	2.3	17
6	Evaluation of Six Weekly Oral Fecal Microbiota Transplants in People with HIV. Pathogens and Immunity, 2020, 5, 364.	3.1	7
7	Fibrogenic Gene Expression in Hepatic Stellate Cells Induced by HCV and HIV Replication in a Three Cell Co-Culture Model System. Scientific Reports, 2019, 9, 568.	3.3	17
8	Serum Bovine Immunoglobulins Improve Inflammation and Gut Barrier Function in Persons with HIV and Enteropathy on Suppressive ART. Pathogens and Immunity, 2019, 4, 124.	3.1	10
9	Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments. Clinical Infectious Diseases, 2018, 66, 1540-1549.	5.8	32
10	Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 216, 813-818.	4.0	12
11	Evaluation of oral serum-derived bovine immunoglobulins in HIV-infected patients with chronic idiopathic diarrhea. HIV Clinical Trials, 2017, 18, 205-213.	2.0	2
12	Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection. Clinical Infectious Diseases, 2017, 64, 124-131.	5.8	200
13	A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy. Open Forum Infectious Diseases, 2017, 4, ofw278.	0.9	58
14	Circulating LOXL2 Levels Reflect Severity of Intestinal Fibrosis and GALT CD4+ T Lymphocyte Depletion in Treated HIV Infection. Pathogens and Immunity, 2017, 2, 239.	3.1	2
15	Interferons and HIV Infection: The Good, the Bad, and the Ugly. Pathogens and Immunity, 2016, 1, 107.	3.1	72
16	Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients NaÃ-ve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathogens, 2016, 12, e1005381.	4.7	37
17	MRSA Infections in HIV-Infected People Are Associated with Decreased MRSA-Specific Th1 Immunity. PLoS Pathogens, 2016, 12, e1005580.	4.7	22
18	Long-term Use of Proton Pump Inhibitors and Increased Immune Activation in Patients With Chronic HIV-1 Infection. Open Forum Infectious Diseases, 2016, 3, .	0.9	0

#	Article	IF	CITATIONS
19	Unchanged Levels of Soluble CD14 and IL-6 Over Time Predict Serious Non-AIDS Events in HIV-1-Infected People. AIDS Research and Human Retroviruses, 2016, 32, 1205-1209.	1.1	20
20	Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era. Tropical Diseases, Travel Medicine and Vaccines, 2016, 2, 21.	2.2	15
21	Peginterferon α-2a for the treatment of HIV infection. Expert Opinion on Investigational Drugs, 2016, 25, 249-257.	4.1	7
22	Role of immune activation in progression to AIDS. Current Opinion in HIV and AIDS, 2016, 11, 131-137.	3.8	58
23	A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS. Clinical Infectious Diseases, 2016, 62, 258-261.	5.8	45
24	Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1126-34.	7.1	252
25	T-Cell Depletion in the Colonic Mucosa of Patients With Idiopathic CD4+Lymphopenia. Journal of Infectious Diseases, 2015, 212, 1579-1587.	4.0	14
26	Type I Interferon: Understanding Its Role in HIV Pathogenesis and Therapy. Current HIV/AIDS Reports, 2015, 12, 41-53.	3.1	90
27	Elite Control, Gut CD4 T Cell Sparing, and Enhanced Mucosal T Cell Responses in Macaca nemestrina Infected by a Simian Immunodeficiency Virus Lacking a gp41 Trafficking Motif. Journal of Virology, 2015, 89, 10156-10175.	3.4	19
28	Initiation of ART during Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation. PLoS Pathogens, 2014, 10, e1004543.	4.7	218
29	Can early therapy reduce inflammation?. Current Opinion in HIV and AIDS, 2014, 9, 72-79.	3.8	41
30	Sevelamer Does Not Decrease Lipopolysaccharide or Soluble CD14 Levels But Decreases Soluble Tissue Factor, Low-Density Lipoprotein (LDL) Cholesterol, and Oxidized LDL Cholesterol Levels in Individuals With Untreated HIV Infection. Journal of Infectious Diseases, 2014, 210, 1549-1554.	4.0	80
31	Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature, 2014, 511, 601-605.	27.8	422
32	Safety and tolerability of a live oral Salmonella typhimurium vaccine candidate in SIV-infected nonhuman primates. Vaccine, 2013, 31, 5879-5888.	3.8	19
33	Characteristics of Congenital Hepatic Fibrosis in a Large Cohort of Patients With Autosomal Recessive Polycystic Kidney Disease. Gastroenterology, 2013, 144, 112-121.e2.	1.3	153
34	Neither Microbial Translocation Nor TLR Responsiveness Are Likely Explanations for Preexisting Immune Activation in Women Who Subsequently Acquired HIV in CAPRISA 004. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 294-298.	2.1	6
35	Suppressed Th17 Levels Correlate with Elevated PIAS3, SHP2, and SOCS3 Expression in CD4 T Cells during Acute Simian Immunodeficiency Virus Infection. Journal of Virology, 2013, 87, 7093-7101.	3.4	33
36	Study design issues in evaluating immune biomarkers. Current Opinion in HIV and AIDS, 2013, 8, 147-154.	3.8	7

#	Article	lF	CITATION
37	Loss of a Tyrosine-Dependent Trafficking Motif in the Simian Immunodeficiency Virus Envelope Cytoplasmic Tail Spares Mucosal CD4 Cells but Does Not Prevent Disease Progression. Journal of Virology, 2013, 87, 1528-1543.	3.4	32
38	Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. Aids, 2013, 27, 2207-2217.	2.2	63
39	Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation. Haematologica, 2012, 97, 867-873.	3.5	34
40	Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nature Reviews Microbiology, 2012, 10, 655-666.	28.6	373
41	CD4 T follicular helper cell dynamics during SIV infection. Journal of Clinical Investigation, 2012, 122, 3281-3294.	8.2	307
42	Host Response to Translocated Microbial Products Predicts Outcomes of Patients With HBV or HCV Infection. Gastroenterology, 2011, 141, 1220-1230.e3.	1.3	268
43	Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection. Journal of Infectious Diseases, 2011, 203, 780-790.	4.0	957
44	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. Journal of Clinical Investigation, 2011, 121, 2391-2400.	8.2	168
45	Th17 cells, Jobʽs syndrome and HIV: opportunities for bacterial and fungal infections. Current Opinion in HIV and AIDS, 2010, 5, 179-183.	3.8	45
46	Hypomorphic Rag mutations can cause destructive midline granulomatous disease. Blood, 2010, 116, 1263-1271.	1.4	110
47	An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist. New England Journal of Medicine, 2009, 360, 2426-2437.	27.0	892
48	P-selectin suppresses hepatic inflammation and fibrosis in mice by regulating interferon? and the IL-13 decay receptor. Hepatology, 2004, 39, 676-687.	7.3	32